


Atazanavir

| | |
|---------------------------|---|
| Cat. No.: | HY-17367 |
| CAS No.: | 198904-31-3 |
| Molecular Formula: | C ₃₈ H ₅₂ N ₆ O ₇ |
| Molecular Weight: | 704.86 |
| Target: | HIV; HIV Protease; Cytochrome P450; P-glycoprotein; SARS-CoV; Endogenous Metabolite |
| Pathway: | Anti-infection; Metabolic Enzyme/Protease; Membrane Transporter/Ion Channel |
| Storage: | Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month |



SOLVENT & SOLUBILITY

In Vitro

DMSO : 83.33 mg/mL (118.22 mM; Need ultrasonic)

| Concentration | Mass | | |
|---------------|-----------|-----------|------------|
| | 1 mg | 5 mg | 10 mg |
| 1 mM | 1.4187 mL | 7.0936 mL | 14.1872 mL |
| 5 mM | 0.2837 mL | 1.4187 mL | 2.8374 mL |
| 10 mM | 0.1419 mL | 0.7094 mL | 1.4187 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration^[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)^[2]. Atazanavir is also a SARS-CoV 3CL^{Pro} inhibitor with an IC₅₀ of 3.49 μM^[3].

IC₅₀ & Target

CYP3 HIV-1

CUSTOMER VALIDATION

- Signal Transduct Target Ther. 2021 May 29;6(1):212.
- Nat Commun. 2020 Sep 4;11(1):4417.
- Int J Antimicrob Agents. 2019 Dec;54(6):814-819.
- PLoS Biol. 2020 Jan 16;18(1):e3000599.

-
- Aging Cell. 2022 Dec 20;e13750.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Havlir DV, et al. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis. 2004 Jun 1;38(11):1599-604.

[2]. Wood R. Atazanavir: its role in HIV treatment. Expert Rev Anti Infect Ther. 2008 Dec;6(6):785-96.

[3]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA